peaking today.
The March 3 announcement detailed intentions to launch a Phase 2 study in Q3 2026 targeting adults with phlebotomy-dependent PV, emphasizing potential for early hematocrit control based on preclinical data showing rapid, sustained reductions. This positive pipeline expansion triggered initial surge on March 4 (close +26% on elevated volume), with momentum building through trader digestion and retail interest, as seen in volume spikes to 1.5M shares on March 5 (+28%) and 667K on March 6 (+24% from open). No counter-news emerged, sustaining biotech optimism amid low-float dynamics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.